References
- Gauderer MW, Ponsky JL, Izant RJJr. Gastrostomy without laparotomy: a percutaneous endoscopic technique. J Pediatr Surg 1980;15:872–5.
- Loser C, Aschl G, Hebuterne X, Mathus-Vliegen EM, Muscaritoli M, Niv Y, et al. ESPEN guidelines on artificial enteral nutrition--percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005;24:848–61.
- Kirby DF, Delegge MH, Fleming CR. American Gastroenterological Association technical review on tube feeding for enteral nutrition. Gastroenterology 1995;108:1282–301.
- Ponsky JL, Aszodi A. Percutaneous endoscopic jejunostomy. Am J Gastroenterol 1984;79:113–16.
- Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998;97:175–83.
- Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. CMAJ 2003;168:293–301.
- Marttila RJ, Rinne UK. Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand 1976;53:81–102.
- Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord 1995;10:541–9.
- Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, et al. Age-standardized incidence and prevalence of Parkinson’s disease in a Swedish community. J Clin Epidemiol 1996;49:637–41.
- Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology 1999;52:302–8.
- Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011;26:S1–58.
- Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010;24:119–29.
- Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 1998;55:1–9.
- Lundqvist C. Continuous levodopa for advanced Parkinson’s disease. Neuropsychiatr Dis Treat 2007;3:335–48.
- Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156–63.
- Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999;56:529–35.
- Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2–9; discussion S-11.
- Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044–53.
- Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1977;309:345–9.
- Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol 2006;2:382–92.
- Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677–87.
- Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm 2013;120:1305–20.
- Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1–8.
- Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother 2006;6:1403–11.
- Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007;22:1145–9.
- Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151–66.
- Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results. Mov Disord 2015;30:500–9.
- Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease--long-term experience. Acta Neurol Scand 2001;104:343–8.
- Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005;65:1506–7.
- Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141–9.
- Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218–21.
- Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis 2015;5:165–74.
- Kwon RS, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, et al. Enteral nutrition access devices. Gastrointest Endosc 2010;72:236–48.
- AbbVie. PEG: Percutaneous endoscopic gastrostomy kit 15FR/20FR instructions for use. 2014. Available from http://www.rxabbvie.com/pdf/abbvie_instr_pegtube.pdf. [Cited 12 May 2015].
- Committee ASoP. Levy MJ, Anderson MA, Baron TH, Banerjee S, Dominitz JA, et al. Position statement on routine laboratory testing before endoscopic procedures. Gastrointest Endosc 2008;68:827–32.
- Boustiere C, Veitch A, Vanbiervliet G, Bulois P, Deprez P, Laquiere A, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2011;43:445–61.
- Blomberg J, Lagergren P, Martin L, Mattsson F, Lagergren J. Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial. BMJ 2010;341:c3115.
- Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database Syst Rev 2006;CD005571.
- Metheny N, Eisenberg P, McSweeney M. Effect of feeding tube properties and three irrigants on clogging rates. Nurs Res 1988;37:165–9.
- Reising DL, Neal RS. Enteral tube flushing. Am J Nurs 2005;105:58–63; quiz -4.
- AbbVie. Duodopa Intestinal Gel summary of product characteristics. 2014. Available from http://www.medicines.org.uk/emc/medicine/20786. [Cited 12 May 2015].
- Zopf Y, Konturek P, Nuernberger A, Maiss J, Zenk J, Iro H, et al. Local infection after placement of percutaneous endoscopic gastrostomy tubes: a prospective study evaluating risk factors. Can J Gastroenterol 2008;22:987–91.
- Chung RS, Schertzer M. Pathogenesis of complications of percutaneous endoscopic gastrostomy. A lesson in surgical principles. Am Surg 1990;56:134–7.